ISRCTN15654915已完成未知
Yorkshire Collaborative Small Cell Lung Cancer Study
orthern and Yorkshire Clinical Trials and Research Unit (UK)0 个研究点目标入组 0 人开始时间: 2002年8月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Small cell lung cancer confirmed by histological or bronchial brush or aspirate cytology.
- •2. Aged <75 years
- •3. Normal renal and hepatic function
- •4. No evidence of brain metastases
- •5. No previous specific anti-cancer treatment for current disease
- •6. No other malignant disease, except basal cell carcinoma and in situ carcinoma of the cervix
排除标准
- •Not provided at time of registration
研究者
相似试验
进行中（未招募）
3 期
Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancerimited Stage Small Cell Lung Cancer (LS-SCLC)D055752JPRN-jRCT2031210107Kagamu Hiroshi45
已完成
不适用
tritional Assessment in Non-small Cell lung cancer patientslungcancerNon Small Cell Lung Cancer10038666NL-OMON50451Antoni van Leeuwenhoek Ziekenhuis100
尚未招募
不适用
ung cancer Early Molecular Assessment trial10038666non-small cell lung cancerNL-OMON47319Antoni van Leeuwenhoek Ziekenhuis1,297
进行中（未招募）
不适用
STOMP: Small cell lung cancer Trial of Olaparib (AZD2281) as Maintenance Programme: a randomised, double blind, multicentre phase II trial - STOMP: SCLC Trial of Olaparib (AZD2281) as Maintenance Programme.Small cell lung cancerEUCTR2010-021165-76-GBSheffield Teaching Hospitals NHS Foundation Trust222
已完成
2 期
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-EtoposideSCLC, Extensive StageNCT04221529AIO-Studien-gGmbH70